Tag #Covid-19

Showing 193 to 204 of 236 results

theguardian.com

🌐 90% Global Worthiness

Dec 19, 01:10

Retraction of High-Profile Hydroxychloroquine Covid-19 Study

Elsevier retracted a March 2020 study promoting hydroxychloroquine for Covid-19 due to ethical concerns raised by three of its authors and an investigation revealing issues with patient consent and equipoise, marking the highest-cited retracted Covid-19 paper.

Retraction of High-Profile Hydroxychloroquine Covid-19 Study

Elsevier retracted a March 2020 study promoting hydroxychloroquine for Covid-19 due to ethical concerns raised by three of its authors and an investigation revealing issues with patient consent and equipoise, marking the highest-cited retracted Covid-19 paper.

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What long-term implications does this retraction have for the regulation of drug promotion and the conduct of future Covid-19 research?

This retraction carries significant implications for future research, emphasizing the need for robust ethical standards and rigorous methodology in clinical trials. The controversy underscores the dangers of promoting unproven treatments, especially during public health crises. The event serves as a stark reminder of the necessity of thorough peer review and the importance of transparency in scientific research.

repubblica.it

🌐 85% Global Worthiness

Dec 19, 13:11

Retraction of 2020 Hydroxychloroquine COVID-19 Study Due to Ethical and Methodological Flaws

A 2020 study promoting hydroxychloroquine for COVID-19 treatment, published in the International Journal of Antimicrobial Agents and led by Philippe Gautret, has been retracted due to ethical concerns and methodological flaws, including a small sample size and issues with patient consent for azithro...

Retraction of 2020 Hydroxychloroquine COVID-19 Study Due to Ethical and Methodological Flaws

A 2020 study promoting hydroxychloroquine for COVID-19 treatment, published in the International Journal of Antimicrobial Agents and led by Philippe Gautret, has been retracted due to ethical concerns and methodological flaws, including a small sample size and issues with patient consent for azithro...

Progress

52% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What were the key methodological and ethical flaws in the retracted 2020 study on hydroxychloroquine's efficacy against COVID-19, and what were the immediate consequences of its promotion?

In 2020, a study in the International Journal of Antimicrobial Agents (IJAA) promoted hydroxychloroquine for COVID-19 treatment. This study, led by Philippe Gautret, has now been retracted due to ethical concerns and methodological flaws, including a small sample size of only 36 patients and irregularities in ethical approval and patient consent regarding the use of azithromycin. The retraction follows years of criticism highlighting these issues and potential ethical violations.

elmundo.es

🌐 75% Global Worthiness

Dec 18, 01:09

Spanish Court Clears Andalusian Health Service in Emergency Contract Probe

The Spanish Court of Auditors concluded its investigation into Andalusian Health Service emergency contracts, finding no accounting irregularities despite initial concerns, and the matter remains under judicial investigation.

Spanish Court Clears Andalusian Health Service in Emergency Contract Probe

The Spanish Court of Auditors concluded its investigation into Andalusian Health Service emergency contracts, finding no accounting irregularities despite initial concerns, and the matter remains under judicial investigation.

Progress

36% Bias Score

ShareSaveArticle

Peace, Justice, and Strong Institutions

12345678

Previous 1 of 8 Next

What prompted the investigation, and what role did the Andalusian Audit Office play in the process?

The Court of Auditors investigated potential accounting irregularities in emergency contracts, requesting information from the Andalusian Audit Office. The Audit Office's July 2024 report, initially raising concerns about three contracts, was subsequently deemed to have resolved those concerns, leading to the closure of the investigation in October 2024.

cnbc.com

🌐 75% Global Worthiness

Dec 17, 16:15

Pfizer's 2025 Forecast Meets Expectations Amidst Medicare Changes and Investor Scrutiny

Pfizer projects 2025 profits near analyst estimates, anticipating stable Covid-19 product sales despite a \$1 billion revenue reduction from Medicare changes and ongoing investor pressure following a 12% share decline this year.

Pfizer's 2025 Forecast Meets Expectations Amidst Medicare Changes and Investor Scrutiny

Pfizer projects 2025 profits near analyst estimates, anticipating stable Covid-19 product sales despite a \$1 billion revenue reduction from Medicare changes and ongoing investor pressure following a 12% share decline this year.

Progress

36% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How is Pfizer addressing the criticism regarding its acquisitions and the decline in Covid-19 product sales?

Pfizer's forecast reflects its strategic response to declining Covid-19 product sales and investor criticism. The company's cost-cutting and divestiture strategy aims to offset revenue losses and improve profitability. This follows criticism from Starboard Value regarding overspending on acquisitions and a lack of profitable new drugs.

dailymail.co.uk

🌐 75% Global Worthiness

Dec 16, 19:13

Western Australia Covid-19 Surge: 75 Daily Hospital Admissions

Western Australia is experiencing a surge in Covid-19 cases driven by Omicron subvariants, resulting in an average of 75 daily hospital admissions; authorities urge isolation for anyone with symptoms, mask-wearing in public, and vaccination with the new Pfizer JN.1 booster.

Western Australia Covid-19 Surge: 75 Daily Hospital Admissions

Western Australia is experiencing a surge in Covid-19 cases driven by Omicron subvariants, resulting in an average of 75 daily hospital admissions; authorities urge isolation for anyone with symptoms, mask-wearing in public, and vaccination with the new Pfizer JN.1 booster.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the immediate impact of the rising Covid-19 cases in Western Australia on the healthcare system and public health?

A fresh wave of Covid-19, driven by Omicron subvariants, is surging in Western Australia, leading to an average of 75 daily hospital admissions. Authorities are urging residents with any cold or flu-like symptoms to isolate and wear masks in crowded places to curb the spread, particularly as the peak coincides with the Christmas holidays.

es.euronews.com

🌐 85% Global Worthiness

Dec 14, 16:13

EU Faces Potential "Triple Threat" of Winter Respiratory Viruses

European health agencies warn of a potential "triple threat" of respiratory illnesses this winter, with influenza, RSV, and COVID-19 circulating, straining healthcare systems; increased indoor transmission during winter months contributes to higher infection rates; vaccination and preventive measure...

EU Faces Potential "Triple Threat" of Winter Respiratory Viruses

European health agencies warn of a potential "triple threat" of respiratory illnesses this winter, with influenza, RSV, and COVID-19 circulating, straining healthcare systems; increased indoor transmission during winter months contributes to higher infection rates; vaccination and preventive measure...

Progress

32% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What long-term strategies should be implemented to mitigate the impact of future winter respiratory virus outbreaks?

While COVID-19 cases have decreased this fall, the risk of simultaneous outbreaks of influenza and RSV remains high. Vaccination is crucial, especially for vulnerable groups, along with simple preventive measures such as hand hygiene and staying home when sick. Improving indoor air quality and using FFP2 masks can also help reduce transmission.

abcnews.go.com

🌐 85% Global Worthiness

Dec 19, 01:11

Retracted Hydroxychloroquine Study Highlights Risks of Premature Research and Misinformation

A 2020 study in the International Journal of Antimicrobial Agents promoting hydroxychloroquine as a COVID-19 treatment was retracted due to ethical and methodological concerns raised by the authors and the publisher, Elsevier, impacting researchers' careers and leading to the revocation of the FDA's...

Retracted Hydroxychloroquine Study Highlights Risks of Premature Research and Misinformation

A 2020 study in the International Journal of Antimicrobial Agents promoting hydroxychloroquine as a COVID-19 treatment was retracted due to ethical and methodological concerns raised by the authors and the publisher, Elsevier, impacting researchers' careers and leading to the revocation of the FDA's...

Progress

48% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What were the immediate consequences of the retraction of the hydroxychloroquine study, and how did it impact public health policy?

A 2020 study in the International Journal of Antimicrobial Agents promoting hydroxychloroquine as a COVID-19 treatment has been retracted due to ethical and methodological concerns, impacting researchers' careers and reputations. The retraction followed concerns about research conduct and methodology, raised by some of the authors themselves and flagged by Elsevier, the journal's publisher. The FDA's subsequent emergency use authorization for the drug was revoked after larger studies showed no benefits and potential risks.

nos.nl

🌐 85% Global Worthiness

Dec 19, 19:12

Dutch Entrepreneurs Face Fraud Trial Over COVID-19 Mask Deal

Three Dutch entrepreneurs stand trial in Rotterdam for allegedly defrauding the government and private companies during the COVID-19 pandemic by profiting millions from a mask deal, using a commercial business structure despite claiming non-profit status; the case involves 17,000 pages of evidence a...

Dutch Entrepreneurs Face Fraud Trial Over COVID-19 Mask Deal

Three Dutch entrepreneurs stand trial in Rotterdam for allegedly defrauding the government and private companies during the COVID-19 pandemic by profiting millions from a mask deal, using a commercial business structure despite claiming non-profit status; the case involves 17,000 pages of evidence a...

Progress

48% Bias Score

ShareSaveArticle

Reduced Inequality

12345678

Previous 1 of 8 Next

What are the key accusations against Van Lienden, Damme, and Van Gestel, and what are the potential consequences?

Sywert van Lienden, Bernd Damme, and Camille van Gestel are on trial in Rotterdam, accused of fraud, embezzlement, forgery, and/or money laundering related to a controversial mask deal during the COVID-19 pandemic. The case, involving 17,000 pages of evidence, alleges they profited millions from a deal where they claimed to be acting non-profit, but actually used a commercial entity. Randstad and Coolblue are among those seeking financial restitution.",

lemonde.fr

🌐 85% Global Worthiness

Dec 17, 19:11

Retraction of Landmark Hydroxychloroquine Study for COVID-19

A study co-authored by Didier Raoult promoting hydroxychloroquine for COVID-19 treatment was retracted on December 17, 2023, by the International Journal of Antimicrobial Agents due to multiple ethical and methodological breaches, including concerns over results manipulation and lack of informed con...

Retraction of Landmark Hydroxychloroquine Study for COVID-19

A study co-authored by Didier Raoult promoting hydroxychloroquine for COVID-19 treatment was retracted on December 17, 2023, by the International Journal of Antimicrobial Agents due to multiple ethical and methodological breaches, including concerns over results manipulation and lack of informed con...

Progress

56% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What broader implications does this retraction have for scientific integrity and the processes of peer review and publication?

The retraction highlights serious flaws in the study's methodology, raising concerns about the integrity of research on COVID-19 treatments. The study's findings, which supported using hydroxychloroquine with azithromycin, were subsequently contradicted by larger, more rigorous trials demonstrating its ineffectiveness. The controversy surrounding the study extends beyond scientific circles, having involved political figures such as Emmanuel Macron and Donald Trump, who publicly endorsed the treatment.

welt.de

🌐 75% Global Worthiness

Dec 16, 16:10

Berlin Man Sentenced to 4.5 Years for €4 Million Coronavirus Testing Fraud

A 39-year-old businessman in Berlin was sentenced to four and a half years in prison and ordered to repay nearly €4 million for fraudulently billing the Kassenärztliche Vereinigung for coronavirus tests performed at four centers he operated via a shell company between April 2021 and March 2022.

Berlin Man Sentenced to 4.5 Years for €4 Million Coronavirus Testing Fraud

A 39-year-old businessman in Berlin was sentenced to four and a half years in prison and ordered to repay nearly €4 million for fraudulently billing the Kassenärztliche Vereinigung for coronavirus tests performed at four centers he operated via a shell company between April 2021 and March 2022.

Progress

44% Bias Score

ShareSaveArticle

Reduced Inequality

12345678

Previous 1 of 8 Next

What were the motivations behind the fraudulent activities of the 39-year-old businessman, and what role did his accomplices play?

The defendant, a businessman with prior involvement in construction and real estate, admitted to the scheme, stating that he was motivated by financial difficulties, including gambling losses, and awareness of lax oversight by the KV. His actions involved three accomplices and four testing centers across Berlin, with approximately 180,000 tests conducted but far more falsely billed.

nos.nl

🌐 85% Global Worthiness

Dec 14, 12:25

Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Despite Reduced COVID-19 Sales

Pfizer's Dutch subsidiary reported an $11.4 billion profit for the year ending November 2023, down from previous years due to decreased COVID-19 vaccine and treatment sales, but still comparable to pre-pandemic levels; the subsidiary manages operations for most Pfizer entities outside the U.S.

Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Despite Reduced COVID-19 Sales

Pfizer's Dutch subsidiary reported an $11.4 billion profit for the year ending November 2023, down from previous years due to decreased COVID-19 vaccine and treatment sales, but still comparable to pre-pandemic levels; the subsidiary manages operations for most Pfizer entities outside the U.S.

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

What is the overall impact of decreased COVID-19 vaccine demand on Pfizer's profits, and what specific financial figures illustrate this impact?

Pfizer's Dutch subsidiary, C.P. Pharmaceuticals International C.V., reported a $11.4 billion profit for the period December 2022 to November 2023. This is lower than during the COVID-19 crisis but still significant, representing a return to pre-pandemic profit levels. The decrease is primarily due to reduced sales of Comirnaty vaccines and Paxlovid medications.

nos.nl

🌐 75% Global Worthiness

Dec 14, 12:25

Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Amidst Reduced COVID-19 Vaccine Sales

Pfizer's Dutch subsidiary reported an $11.4 billion profit for the fiscal year ending November 2023, down from previous years due to reduced COVID-19 vaccine and medication sales, but comparable to pre-pandemic levels; the company's revenue decreased from $74.4 billion in 2022 to $46.9 billion in 20...

Pfizer's Dutch Subsidiary Reports $11.4 Billion Profit Amidst Reduced COVID-19 Vaccine Sales

Pfizer's Dutch subsidiary reported an $11.4 billion profit for the fiscal year ending November 2023, down from previous years due to reduced COVID-19 vaccine and medication sales, but comparable to pre-pandemic levels; the company's revenue decreased from $74.4 billion in 2022 to $46.9 billion in 20...

Progress

40% Bias Score

ShareSaveArticle

Good Health and Well-being

12345678

Previous 1 of 8 Next

How did the Dutch subsidiary's role in channeling profits from various countries contribute to Pfizer's overall financial picture?

The significant drop in Pfizer's revenue from $74.4 billion in 2022 to $46.9 billion in 2023 is primarily attributed to the decreased demand for Comirnaty and Paxlovid. While this decline impacts Pfizer's overall profits, the company's Dutch subsidiary still oversees the majority of Pfizer's international operations outside of the U.S., channeling profits through the Netherlands.

Showing 193 to 204 of 236 results